JP2022503850A - 産物及び組成物 - Google Patents

産物及び組成物 Download PDF

Info

Publication number
JP2022503850A
JP2022503850A JP2021517420A JP2021517420A JP2022503850A JP 2022503850 A JP2022503850 A JP 2022503850A JP 2021517420 A JP2021517420 A JP 2021517420A JP 2021517420 A JP2021517420 A JP 2021517420A JP 2022503850 A JP2022503850 A JP 2022503850A
Authority
JP
Japan
Prior art keywords
nucleic acid
moiety
construct
moieties
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021517420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022503850A5 (https=
JPWO2020065602A5 (https=
Inventor
サマルスキー，ドミトリー
Original Assignee
サーナオミクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サーナオミクス インコーポレイテッド filed Critical サーナオミクス インコーポレイテッド
Publication of JP2022503850A publication Critical patent/JP2022503850A/ja
Publication of JP2022503850A5 publication Critical patent/JP2022503850A5/ja
Publication of JPWO2020065602A5 publication Critical patent/JPWO2020065602A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/313—Phosphorodithioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
JP2021517420A 2018-09-28 2019-09-27 産物及び組成物 Pending JP2022503850A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862738222P 2018-09-28 2018-09-28
US62/738,222 2018-09-28
PCT/IB2019/058221 WO2020065602A2 (en) 2018-09-28 2019-09-27 Products and compositions

Publications (3)

Publication Number Publication Date
JP2022503850A true JP2022503850A (ja) 2022-01-12
JP2022503850A5 JP2022503850A5 (https=) 2022-09-28
JPWO2020065602A5 JPWO2020065602A5 (https=) 2022-09-28

Family

ID=69951906

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021517420A Pending JP2022503850A (ja) 2018-09-28 2019-09-27 産物及び組成物

Country Status (11)

Country Link
US (1) US20210371861A1 (https=)
EP (1) EP3856200A4 (https=)
JP (1) JP2022503850A (https=)
KR (1) KR20210093851A (https=)
CN (1) CN113164507A (https=)
AU (1) AU2019346148A1 (https=)
BR (1) BR112021005777A2 (https=)
CA (1) CA3110300A1 (https=)
IL (1) IL281684A (https=)
WO (1) WO2020065602A2 (https=)
ZA (1) ZA202101298B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250000892A1 (en) * 2021-10-14 2025-01-02 Arizona Board Of Regents On Behalf Of Arizona State University Programmable delivery platforms for rna structures
WO2023069707A2 (en) * 2021-10-22 2023-04-27 Sirnaomics, Inc. Products and compositions
WO2023240249A1 (en) * 2022-06-11 2023-12-14 Sirnaomics, Inc. Products and compositions
WO2024059873A2 (en) * 2022-09-16 2024-03-21 Sirnaomics, Inc. Products and compositions
WO2024081922A1 (en) * 2022-10-14 2024-04-18 Arizona Board Of Regents On Behalf Of Arizona State University Modular rna delivery platforms and methods of their use
WO2024164001A2 (en) * 2023-02-03 2024-08-08 Sirnaomics, Inc. Products and compositions
WO2024216267A2 (en) * 2023-04-14 2024-10-17 Sirnaomics, Inc. Products and compositions
WO2024229229A2 (en) * 2023-05-02 2024-11-07 Sirnaomics, Inc. Products and compositions
TW202526017A (zh) 2023-09-14 2025-07-01 美商Ionis製藥公司 用於減少ａｐｏｃｉｉｉ表現的化合物及方法
WO2025064821A2 (en) 2023-09-21 2025-03-27 Ionis Pharmaceuticals, Inc. Compounds and methods for inhibiting lpa
WO2025259875A1 (en) * 2024-06-12 2025-12-18 Sirnaomics, Inc. Novel antibody oligonucleotide drug conjugates containing gemcitibine for pharmaceutical compositions and related methods of use and treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007091269A2 (en) * 2006-02-08 2007-08-16 Quark Pharmaceuticals, Inc. NOVEL TANDEM siRNAS
US20180105815A1 (en) * 2016-10-18 2018-04-19 Augusta University Research lnstitute, lnc. Bivalent siRNA Chimeras and Methods of Use Thereof
JP2018518186A (ja) * 2015-06-15 2018-07-12 エムペグ エルエイ リミテッド ライアビリティ カンパニー 定義されたマルチコンジュゲートオリゴヌクレオチド
CN108342386A (zh) * 2017-01-22 2018-07-31 广州市锐博生物科技有限公司 一种多聚寡核酸分子及其在多靶标干扰中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252526B2 (en) * 2006-11-09 2012-08-28 Gradalis, Inc. ShRNA molecules and methods of use thereof
EP2318528A1 (en) * 2008-07-24 2011-05-11 Rxi Pharmaceuticals Corporation Rnai constructs and uses therof
EP2395085B1 (en) * 2009-02-04 2015-06-10 Sungkyunkwan University Foundation for Corporate Collaboration Small interference rna complex with increased intracellular transmission capacity
ES2804764T3 (es) * 2009-06-01 2021-02-09 Halo Bio Rnai Therapeutics Inc Polinucleótidos para la interferencia de ARN multivalente, composiciones y métodos de uso de los mismos
WO2015164818A1 (en) * 2014-04-25 2015-10-29 Strike Bio, Inc. Multiple targeted rnai for the treatment of cancers
EP4365291A3 (en) * 2015-06-12 2024-08-14 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
WO2020014948A1 (zh) * 2018-07-20 2020-01-23 广州市锐博生物科技有限公司 核酸单元及其聚合核酸与应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007091269A2 (en) * 2006-02-08 2007-08-16 Quark Pharmaceuticals, Inc. NOVEL TANDEM siRNAS
JP2018518186A (ja) * 2015-06-15 2018-07-12 エムペグ エルエイ リミテッド ライアビリティ カンパニー 定義されたマルチコンジュゲートオリゴヌクレオチド
US20180105815A1 (en) * 2016-10-18 2018-04-19 Augusta University Research lnstitute, lnc. Bivalent siRNA Chimeras and Methods of Use Thereof
CN108342386A (zh) * 2017-01-22 2018-07-31 广州市锐博生物科技有限公司 一种多聚寡核酸分子及其在多靶标干扰中的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GRIJALVO, S. ET AL., GENES, vol. Vol. 9:74, JPN6023029663, 6 February 2018 (2018-02-06), pages 1 - 38, ISSN: 0005567419 *
NAKASHIMA Y. ET AL., CHEMICAL COMMUNICATIONS, vol. 47, JPN6023034913, 2011, pages 8367 - 8369, ISSN: 0005567418 *
PARMAR, R. ET AL., CHEMBIOCHEM, vol. 17, JPN6023029662, 2016, pages 985 - 989, ISSN: 0005567420 *

Also Published As

Publication number Publication date
WO2020065602A2 (en) 2020-04-02
BR112021005777A2 (pt) 2022-04-19
ZA202101298B (en) 2024-06-26
EP3856200A4 (en) 2022-07-20
IL281684A (en) 2021-05-31
CA3110300A1 (en) 2020-04-02
KR20210093851A (ko) 2021-07-28
CN113164507A (zh) 2021-07-23
US20210371861A1 (en) 2021-12-02
WO2020065602A3 (en) 2020-06-25
AU2019346148A1 (en) 2021-05-27
EP3856200A2 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
JP2022503850A (ja) 産物及び組成物
EP1737879B1 (en) Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
Toub et al. Innovative nanotechnologies for the delivery of oligonucleotides and siRNA
KR101752812B1 (ko) 고효율 나노입자형 이중나선 올리고 rna 구조체 및 그의 제조방법
JP2019503394A (ja) 分岐オリゴヌクレオチド
JP2021533804A5 (https=)
JP2022503850A5 (https=)
KR20240099322A (ko) 조건-활성화가능한 핵산 구축물 및 신경계 질환을 치료하기 위한 그의 용도
KR100929699B1 (ko) 다수 표적 유전자들을 제어하는 간섭 유도 ｒｎａ들 및그들의 제조방법
US20210332358A1 (en) MINIATURIZED HAIRPIN RNAi TRIGGERS (mxRNA) AND METHODS OF USES THEREOF
JPWO2020065602A5 (https=)
JP7213897B2 (ja) 核酸ユニットとその高分子核酸及びその応用
Haque et al. Overview of methods in RNA nanotechnology: synthesis, purification, and characterization of RNA nanoparticles
Pérez et al. MicroRNA interference
HK40057705A (en) Multi-targeting nucleic acid constructs composed of multiple oligonucleotides that modulate gene expression through complimentary interactions with targets
CN117795072A (zh) 产品和组合物
HK40058459A (en) Miniaturized hairpin rnai triggers (mxrna) and methods of uses thereof
WO2023212327A1 (en) Protecting oligonucleotides for crispr guide rna
WO2018014848A1 (zh) 一种小rna抑制剂
Zhang et al. Antisense technology
KR100929700B1 (ko) 일부 단일가닥의 다중 간섭 유도 ｒｎａ
KR20090014676A (ko) 짧은 길이의 간섭 유도 ｒｎａ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230829

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240229

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240829

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250408

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251007